Skip to main content
ARS Home » Plains Area » Houston, Texas » Children's Nutrition Research Center » Research » Publications at this Location » Publication #176771
Title: GLP-2 TREATMENT DURING CHRONIC TPN IMPROVES INTESTINAL GLUCOSE UPTAKE AFTER RE-FEEDING IN PIGLETS

Author
item COTTRELL, JEREMY - BAYLOR COLL MEDICINE
item STOLL, BARBARA - BAYLOR COLL MEDICINE
item BUDDINGTON, RANDY - MISSISSIPPI STATE UNIV.
item RIEDIJK, MAAIKE - SOPHIA HOSP, NETHERLANDS
item STEPHENS, JOHN - BAYLOR COLL MEDICINE
item CUI, LIWEI - BAYLOR COLL MEDICINE
item CHANG, XIOYAN - BAYLOR COLL MEDICINE
item Burrin, Douglas - Doug

Submitted to: Journal of Federation of American Societies for Experimental Biology
Publication Type: Abstract Only
Publication Acceptance Date: 1/1/2005
Publication Date: 4/1/2005
Citation: Cottrell, J., Stoll, B., Buddington, R., Riedijk, M., Stephens, J., Cui, L., Chang, X., Burrin, D.G. 2005. GLP-2 treatment during chronic tpn improves intestinal glucose uptake after re-feeding in piglets. Journal of Federation of American Societies for Experimental Biology. 19:A1695.

Interpretive Summary: Interpretive Summary not needed for this 115.

Technical Abstract: Intestinal atrophy and lower nutrient absorption caused by chronic total parenteral nutrition (TPN) compromises the transition to enteral feeding. We examined whether providing glucagon-like peptide 2 (GLP-2) during TPN improved this transition by comparing neonatal piglets maintained for 7 d on enteral formula (ENT), TPN and TPN with GLP-2 (500 pmol/kg/h) and then provided for 6-h with an enteral formula. GLP-2 partially protected against the TPN induced loss in intestinal weight (50a, 29b, 38c g/kg for ENT, TPN, GLP-2), villus height (1199a, 405b, 809c 'm), and total intestinal lactase activity (7703a, 2568b, 4404c mmol/min). Providing GLP-2 increased in vitro rates of glucose transport compared to TPN alone (Vmax = 4.08a, 1.76b, 3.25c nmol/mg-min), consistent with higher total glucose transport capacity. The improved uptake capacity was reflected by improved in vivo net portal glucose (97a, 58b, 31c% of intake) and galactose absorption (57a, 27b,51a %), despite lower portal blood flow in the GLP-2 group compared to the TPN group (4.31ab, 4.88a, 3.62ab L/kg/h). Mucosal lactate production in the GLP-2 group was intermediate between ENT and TPN (0.33a, 1.44b, 0.92ab mmol/kg/h). We conclude that providing GLP-2 during chronic TPN improved intestinal digestive and absorptive capacity parallel with improvements in mucosal structure. Therefore, it is likely that GLP-2 will augment the transition to enteral feeding.